• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

    1/13/25 8:00:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COGT alert in real time by email

    •   Plan to report top-line results from registration-directed SUMMIT trial in NonAdvSM patients in July 2025

    •   Plan to report top-line results from pivotal PEAK Phase 3 trial in 2nd-line GIST patients by end of 2025

    •   Plan to report top-line results from registration-directed APEX trial in AdvSM patients in 2H 2025

    •   Company to present at J.P. Morgan 43rd annual healthcare conference tomorrow, Tuesday, January 14 at 7:30 a.m. PT /10:30 a.m. ET

    WALTHAM, Mass. and BOULDER, Colo., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company's key 2025 milestones ahead of its presentation at J.P. Morgan's 43rd annual healthcare conference.

    "2025 will be a transformational year at Cogent Biosciences," said Andrew Robbins, President and Chief Executive Officer. "During the year, we plan to report top-line results from all three registration-directed bezuclastinib studies, and if successful, move forward with our first New Drug Application (NDA) submission by the end of 2025. With both SUMMIT and PEAK enrollment finishing several months ahead of schedule, we are confident that physicians and patients are highly aware of bezuclastinib's potential and are also eagerly awaiting these clinical trial results. We believe bezuclastinib could change the lives of thousands of patients fighting SM and GIST and has the potential to be the first potent, CNS-sparing, selective KIT mutant inhibitor. In addition, we continue to advance our pipeline of novel small molecule programs, including an ongoing Phase 1 study of our novel FGFR2 inhibitor, CGT4859, and plan to file INDs for both our ErbB2 and PI3Kα programs during the year. With a strong balance sheet, we are well positioned to prepare Cogent for our evolution into a commercial-stage company."

    In 2025, the Company plans to achieve the following milestones:

    Bezuclastinib – Systemic Mastocytosis (SM)

    • Report top-line results in July 2025 from the SUMMIT trial. SUMMIT is a registration-directed, global, randomized, placebo-controlled trial of bezuclastinib in patients with Non-Advanced Systemic Mastocytosis (NonAdvSM).



    • Report top-line results during the second half of 2025 from the APEX trial. APEX is a registration-directed, global, open-label trial of bezuclastinib in patients with Advanced Systemic Mastocytosis (AdvSM).



    • Submit the first bezuclastinib New Drug Application (NDA) by the end of 2025.

    Bezuclastinib – Gastrointestinal Stromal Tumors (GIST)

    • Report top-line results by the end of 2025 from the pivotal Phase 3 PEAK trial. PEAK is a global, blinded, randomized clinical trial studying the combination of bezuclastinib and sunitinib versus sunitinib alone in patients with imatinib-resistant gastrointestinal stromal tumors (GIST).

    Bezuclastinib - Expanded Access Program

    • During Q1 2025, initiate Expanded Access Programs (EAP) in the U.S. for SM and GIST patients to receive investigational bezuclastinib after meeting certain eligibility criteria.

    CGT4859 (FGFR2 inhibitor)

    • Enroll patients in the ongoing Phase 1 trial with CGT4859, a reversible, selective FGFR2 inhibitor in patients with documented FGFR mutations, including advanced cholangiocarcinoma. The trial is designed to explore the safety, tolerability and clinical activity of escalating doses of CGT4859 with a goal of selecting an active and well tolerated dose for further clinical investigation.

    Preclinical Pipeline

    • Submit an IND application for CGT4255, a potent, selective ErbB2 inhibitor, highlighted by potential best-in-class brain-penetrant properties.



    • Submit an IND application for CGT6737, a potent allosteric inhibitor of PI3Kα, with 25-fold selectivity over PI3Kα WT.

    J.P. Morgan Presentation Details

    Cogent will participate in a presentation and Q&A session at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at 7:30 a.m. PT (10:30 a.m. ET). A live webcast will be accessible in the "Investors & Media" section of the company's website, www.cogentbio.com, and will be archived for 30 days following the event.

    Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Cogent also announced today that, on January 7, 2025, the Compensation Committee of Cogent's Board of Directors, made up entirely of independent directors, approved the grant of "inducement" equity awards to nine new employees under the company's 2020 Inducement Plan with a grant date of January 13, 2025. The awards were approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The employees received, in the aggregate, nonqualified options to purchase 135,000 shares of Cogent common stock. Each option has a 10-year term, an exercise price equal to the closing price of Cogent's common stock on the grant date, and a 4-year vesting schedule with 25% vesting on the 1-year anniversary of the grant date and the remainder vesting in equal monthly installments over the subsequent 36 months, provided such employee remains employed through each such vesting date.

    About Cogent Biosciences, Inc.

    Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: plans to report top-line results from SUMMIT in July 2025; plans to report top-line results from PEAK by the end of 2025; plans to report top-line results from APEX in the second half of 2025; plans to file the company's first NDA by the end of 2025; plans to file INDs for the company's ErbB2 and PI3Kα programs in 2025; plans to initiate EAPs in the United States for SM and GIST patients in the first quarter of 2025 and clinical development plans and timelines for the company's ongoing Phase 1 trial with CGT4859. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Cogent's most recent Quarterly Report on Form 10-Q filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

    Contact:

    Christi Waarich

    Senior Director, Investor Relations

    [email protected]

    617-830-1653



    Primary Logo

    Get the next $COGT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COGT

    DatePrice TargetRatingAnalyst
    3/7/2025$17.00Sector Outperform
    Scotiabank
    12/11/2024Buy → Hold
    Needham
    2/26/2024$14.00 → $8.00Outperform → Neutral
    Robert W. Baird
    2/8/2024$11.00Buy
    Citigroup
    12/11/2023$5.00Outperform → Neutral
    Wedbush
    12/8/2023$18.00Overweight
    JP Morgan
    4/28/2023$20.00Outperform
    Robert W. Baird
    3/27/2023$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $COGT
    SEC Filings

    See more
    • SEC Form EFFECT filed by Cogent Biosciences Inc.

      EFFECT - Cogent Biosciences, Inc. (0001622229) (Filer)

      5/12/25 12:15:02 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Cogent Biosciences Inc.

      10-Q - Cogent Biosciences, Inc. (0001622229) (Filer)

      5/6/25 9:00:20 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cogent Biosciences, Inc. (0001622229) (Filer)

      5/6/25 8:19:30 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COGT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cogent Biosciences Reports First Quarter 2025 Financial Results

      Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected by end of year Ended 1Q 2025 with $245.7 million in cash, sufficient to fund operations into late 2026 WALTHAM, Mass. and BOULDER, Colo., May 06, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 was very productive for Cogent

      5/6/25 8:00:00 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders

      WALTHAM, Mass. and BOULDER, Colo., April 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from four pipeline programs during poster sessions at the American Association for Cancer Research (AACR) 2025 Annual Meeting taking place in Chicago. "We welcome the opportunity to present updated results from these programs that represent our exciting pipeline of potential best-in-class targeted therapies," said Andrew Robbins, Cogent's President and Chief Executive Officer. "These data demonstrate Cogent's ability to discover and advance novel the

      4/25/25 8:08:47 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

      WALTHAM, Mass. and BOULDER, Colo., March 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced four preclinical poster presentations at the upcoming 2025 AACR Annual Meeting being held in Chicago, IL April 25-30, 2025. Poster Details Title: Identification of a potent KRAS (ON) inhibitor with selectivity for mutant KRAS over HRAS and NRASSession Category: ChemistrySession Title: Lead Identification and OptimizationSession Date and Time: April 30, 2025 - 9:00 AM – 12:00 PM CT (10:00 AM – 1:00 PM ET)Location: Poster Section 25Poster Board Number: 3Published Abst

      3/25/25 4:31:00 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COGT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Cogent Biosciences with a new price target

      Scotiabank initiated coverage of Cogent Biosciences with a rating of Sector Outperform and set a new price target of $17.00

      3/7/25 8:04:46 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences downgraded by Needham

      Needham downgraded Cogent Biosciences from Buy to Hold

      12/11/24 7:28:07 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Cogent Biosciences from Outperform to Neutral and set a new price target of $8.00 from $14.00 previously

      2/26/24 7:27:30 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COGT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Pinnow Cole bought $332,412 worth of shares (43,750 units at $7.60), increasing direct ownership by 2,085% to 45,848 units (SEC Form 4)

      4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

      1/15/25 7:00:04 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COGT
    Leadership Updates

    Live Leadership Updates

    See more
    • Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

      WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients

      5/23/24 5:05:00 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development

      WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Rachael Easton, MD, Ph.D., Vice President, Head of Clinical Development. "We are pleased to welcome Dr. Easton to Cogent as we continue to develop bezuclastinib in Systemic Mastocytosis and GIST," said Andrew Robbins, the company's President and Chief Executive Officer. "Dr. Easton is an accomplished physician-scientist who brings a wealth of experience in both early and late-stage clinical development across multiple therapeutic areas. Her backgrou

      11/28/22 4:15:00 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer

      CAMBRIDGE, Mass. and BOULDER, Colo., May 3, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Evan Kearns as Chief Legal Officer. In his new role, Mr. Kearns will oversee all corporate legal operations for Cogent Biosciences. "I am excited to welcome Evan to the Cogent team as our Chief Legal Officer," said Andrew Robbins, President and Chief Executive Officer of Cogent Biosciences. "Evan's expert counsel and proven leadership in ad

      5/3/21 7:00:00 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COGT
    Financials

    Live finance-specific insights

    See more
    • Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting

      WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced upcoming presentations for bezuclastinib at the 64th Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, LA from December 10-13, 2022. The company will also host a virtual investor event on December 12 that will be accessible via conference call and webcast, with full details to be made available closer to the date. Oral presentation details: Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Nov

      11/3/22 9:05:00 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

      All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment All bone marrow biopsy-assessed patients achieved ≥50% bone marrow mast cell reduction and decreases in blood KIT D816V variant allele fraction (VAF) Bezuclastinib demonstrates favorable initial safety and tolerability profile with no reported periorbital or peripheral edema, cognitive effects or intracranial bleeding events  Cogent to host investor conference call and webcast today at 8:00 a.m. ET  CAMBRIDGE, Mass. and BOULDER, Colo., June 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biote

      6/10/22 7:00:00 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ferrante Karen Jean

      4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

      4/3/25 4:05:21 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Green John L.

      4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

      1/27/25 5:03:58 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Pinnow Cole

      4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

      1/27/25 5:00:07 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

      SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

      11/14/24 7:59:55 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

      SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

      11/14/24 5:47:15 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

      SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

      11/14/24 4:05:10 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care